BeiGene Ltd. (BGNE)

124.36
0.04 0.03
NASDAQ : Health Technology
Prev Close 124.40
Open 124.96
Day Low/High 123.79 / 125.50
52 Wk Low/High 105.19 / 194.56
Volume 160.58K
Avg Volume 272.90K
Exchange NASDAQ
Shares Outstanding 59.77M
Market Cap 7.34B
EPS -12.10
P/E Ratio N/A
Div & Yield N.A. (N.A)
Allergan, Celgene Offer Solid Biotech Value

Allergan, Celgene Offer Solid Biotech Value

The two giants likely won't be home runs, but they remain stalwarts in the biotech space.

Allergan, Celgene Offer Solid Biotech Value

Allergan, Celgene Offer Solid Biotech Value

The two giants likely won't be home runs, but they remain stalwarts in the biotech space.

Allergan, Celgene Offer Solid Biotech Value

Allergan, Celgene Offer Solid Biotech Value

The two giants likely won't be home runs, but they remain stalwarts in the biotech space.

Celgene Enters PD1 Market with BeiGene Deal

Celgene Enters PD1 Market with BeiGene Deal

Celgene acquired the rights to BeiGene's PD-1 checkpoint inhibitor, propelling the biotech giant forward in immuno-oncology research.

Biotech Movers: Immuno-Oncology Pact With Celgene Sends BeiGene Shares Soaring

Biotech Movers: Immuno-Oncology Pact With Celgene Sends BeiGene Shares Soaring

BeiGene and Impax Laboratories were among the biotech movers in premarket trading on July 6.

Celgene Corporation Enters Into Global Strategic Immuno-Oncology Collaboration With BeiGene To Advance PD-1 Inhibitor Program For Solid Tumor Cancers

Celgene Corporation Enters Into Global Strategic Immuno-Oncology Collaboration With BeiGene To Advance PD-1 Inhibitor Program For Solid Tumor Cancers

Celgene Corporation (NASDAQ:CELG) and BeiGene, Ltd. (NASDAQ:BGNE) entered into a strategic collaboration to develop and commercialize BeiGene's investigational anti-programmed cell death protein 1 (PD-1) inhibitor,...

This Biotech Stock Is Surging More Than 20% Today

This Biotech Stock Is Surging More Than 20% Today

Here are the names.

Presidents Trump and Xi Have 3 Major Issues to Discuss This Week

Presidents Trump and Xi Have 3 Major Issues to Discuss This Week

Currency manipulation, dumping and intellectual property are crucial themes for the meeting.

TheStreet Quant Rating: D (Sell)